Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Feb 16

2023

[News] Grand Opening Ceremony of Hua Medicine's First Online Flagship Store

Hua Medicine (the "Company", HKEx stock code: 2552.HK), today announces that the Company's first online flagship store is inaugurated on 111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform company in China. On February 15th, Dr. Li Chen, the founder and CEO of Hua Medicine, and Dr. Gang Yu, the co-founder and executive chairman of 111, Inc. , jointly announce a grand opening of Hua Medicine’s first online flagship store at the Commercial Launch Event of HuaTangNing (华堂宁®).

Dec 20

2022

[News] WHO Lists Hua Medicine's Innovative First-in-Class Glucokinase Activator (GKA) HuaTangNing in its ATC Classification System

Hua Medicine (the "Company", HKEx stock code: 2552.HK), today announces that the ATC code of HuaTangNing, the Company's first-in-class glucokinase activator (Dorzagliatin tablets) has been formally published as final in WHO Collaborating Center (WHOCC) for Drug Statistics Methodology official website by the World Health Organization (WHO). The ATC code is A10BX18, which will be implemented in the WHO ATC Index in January 2023.

Nov 24

2022

[News] Hua Medicine Appoints Dr. Changhong LI as Chief Scientific Officer to Further Promote the Company's R&D Innovation

Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the appointment of Dr. Changhong LI, an experienced metabolic disease researcher, former member of the Institute of Diabetes, Obesity and Metabolism at the Perelman School of Medicine of the University of Pennsylvania and professional member of the American Diabetes Association

Oct 09

2022

[News] Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing(华堂宁®) Is Approved! New Type 2 Diabetes Treatment Paradigm to Begin in China

Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (华堂宁®) (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved

Aug 25

2022

Hua Medicine Announces 2022 Interim Results

Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2022 (the "Reporting Period"). The NDA for the company's core product dorzagliatin, a first-in-class innovative glucokinase activator (GKA) is under active review by the NMPA. The company is moving forward with preparations for the drug’s life cycle management for expansion of patient population and entering into new indications.

Aug 01

2022

Hua Medicine Announces Multiple Personnel Appointments to Accelerate the Pace of Commercialization

Hua Medicine (the “Company”, stock code: 2552.HK) today announces that Mr. Qing Dong has been appointed as Vice President of the Pharmaceutical Commercialization Division of Hua Medicine. Mr. Qing Dong will be fully responsible for the development of dorzagliatin commercialization strategy and the strategic management of the pharmaceutical commercialization team to accelerate the adoption of dorzagliatin by Type 2 diabetes patients in China.

Jun 07

2022

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).

May 31

2022

Hua Medicine to Present Additional Clinical Results at ADA 2022

Hua Medicine (the "Company", SEHK stock code: 2552.HK) today announced that it will present several clinical results on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions.

May 13

2022

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational drug of the Company for the treatment of diabetes, were published online simultaneously by Nature Medicine, an international top medical journal. These two papers described and analyzed the clinical efficacy and safety characteristics of dorzagliatin monotherapy (SEED) in drug-naïve Type 2 diabetes (T2D) patients and the combination therapy of dorzagliatin and metformin (DAWN) in patients who failed in metformin adequacy therapy for the treatment of T2D respectively.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.